Please wait





03/10/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of common stock, par value $0.00001 per share (the "Common Stock") of AN2 Therapeutics, Inc. (the "Issuer"), which are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percent is based on 35,647,635 shares of the Issuer's Common Stock outstanding, which is the sum of (i) 27,402,024 shares of Common Stock outstanding as of November 3, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025, and (ii) 8,245,611 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on March 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percent is based on 35,647,635 shares of the Issuer's Common Stock outstanding, which is the sum of (i) 27,402,024 shares of Common Stock outstanding as of November 3, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2025, and (ii) 8,245,611 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on March 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percent is based on 35,647,635 shares of the Issuer's Common Stock outstanding, which is the sum of (i) 27,402,024 shares of Common Stock outstanding as of November 3, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2025, and (ii) 8,245,611 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on March 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percent is based on 35,647,635 shares of the Issuer's Common Stock outstanding, which is the sum of (i) 27,402,024 shares of Common Stock outstanding as of November 3, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2025, and (ii) 8,245,611 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on March 10, 2026.


SCHEDULE 13G



 
Vivo Opportunity Fund Holdings, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:03/13/2026
 
Vivo Opportunity, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:03/13/2026
 
Vivo Opportunity Cayman Fund, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:03/13/2026
 
Vivo Opportunity Cayman, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:03/13/2026
Exhibit Information

99.1 Joint Filing Statement